Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

瑋俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

CLARIFICATION ANNOUNCEMENT ON ANNUAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026

Reference is made to the annual results of Wai Chun Bio-Technology Limited (the "**Company**") for the year ended 30 June 2026 published on 13 November 2026 (the "**2026 Annual Results**"). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meaning as defined in the 2026 Annual Results.

The Company would like to clarify that there were clerical errors in Note 14 Share Capital on page 15 of the 2026 Annual Results and the Financial Review on page 17 of the 2026 Annual Results in respect of the Gross Profit. The correct disclosures are as follows:

14. SHARE CAPITAL

Ordinary Shares

Notes:

(c) On 27 April 2026, a holder of the convertible bonds with principal amount of HK$67,000,000 (the "**CB1**") converted partial portion of the CB1 amounted to HK$10,000,000 into 166,666,666 ordinary shares of the Company by crediting the share capital and share premium of approximately HK$1,667,000 and HK$8,353,000 respectively and debiting the liability and equity components of the CB1 of approximately HK$7,270,000 and HK$2,750,000 respectively.

FINANCIAL REVIEW

Gross Profit

The Group recorded a gross profit and gross profit margin of approximately HK$45.3 million and 11.2% respectively for the year ended 30 June 2026, compared to a gross profit of approximately HK$36.0 million and a gross profit margin of approximately 9.5% for the year ended 30 June 2025. The increase in gross profit of approximately HK$9.3 million and gross profit margin of approximately 1.7% in this year was mainly attributable to the increase in revenue and the rose selling prices for small customers.

The above information does not affect any other information contained in the 2026 Annual Results. Save as disclosed herein above, all other information in the 2026 Annual Results remains unchanged.

By order of the Board
Wai Chun Bio-Technology Limited
Lam Ka Chun
Chairman and Executive Director

Hong Kong, 16 November 2026

As at the date of this announcement, the Board comprises:

Executive Director:
Mr. Lam Ka Chun *(Chairman and Chief Executive Officer)*

Independent Non-executive Directors:
Mr. Wong Po Keung
Mr. Wang Ziniu
Ms. Xu Huiling